Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white
blood cells may make the body build an immune response to kill tumor cells. Interleukin-2 may
stimulate a person's white blood cells to kill tumor cells. Vaccines may make the body build
an immune response to kill tumor cells. Combining gene-modified white blood cell infusions
with interleukin-2 and vaccine therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying how well giving gene-modified white blood cells when
given together with interleukin-2 and vaccine therapy works in treating patients with
metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)